Travel And Tourism Unit 3, Axial Scx10iii Release Date, Stearns And Foster Near Me, No 3 Pipe Cutter, Ore Ida Steak Fries Calories, Montgomery County, Pa Schools Reopening, Dewalt Dcs551 Kit, Valrhona Chocolate Fondue, Teenage Mutant Ninja Turtles Cartoon, Marine Parts Near Me Open Today, " /> Travel And Tourism Unit 3, Axial Scx10iii Release Date, Stearns And Foster Near Me, No 3 Pipe Cutter, Ore Ida Steak Fries Calories, Montgomery County, Pa Schools Reopening, Dewalt Dcs551 Kit, Valrhona Chocolate Fondue, Teenage Mutant Ninja Turtles Cartoon, Marine Parts Near Me Open Today, " />

Identify stocks that meet your criteria using seven unique stock screeners. Analysts have given the company’s stock an average 52-week price target of $20, forecast between a low of $20 and high of $20. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. The median estimate represents a +212.50% increase from the last price of 6.40. Standard & Poor's and S&P are registered trademarks of Standard & Poor's Financial Services LLC and Dow Jones is a registered trademark of Dow Jones Trademark Holdings LLC. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. NB-02 focuses on the treatment of neurodegenerative diseases. Get daily stock ideas top-performing Wall Street analysts. View which stocks have been most impacted by COVID-19. NRBO Stock Trend The stock lies in the middle of a very wide and falling trend in the short term and further fall within the trend is signaled. NeuroBo Pharmaceuticals Reports Third Quarter 2020 Financial Results PR Newswire (US) - 11/13/2020 4:30:00 PM Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - … Their forecasts range from $20.00 to $20.00. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. All stock picks. The NeuroBo Pharmaceuticals, Inc. stock holds a sell signal from the short-term moving average; at the same time, however, there is a buy signal from the long-term average. Speculative. To hit the forecast high, the stock’s price needs a +195.86% upsurge from its latest level, while the stock would need to tank 195.86% for it to hit the projected low. The move came on … NeuroBo Pharmaceuticals Inc has fallen lower in 4 of those 4 years over the subsequent 52 week period, corresponding to a historical probability of 100 %. Get short term trading ideas from the MarketBeat Idea Engine. The official website for NeuroBo Pharmaceuticals is www.neurobopharma.com. Vote “Outperform” if you believe NRBO will outperform the S&P 500 over the long term. NeuroBo Pharmaceuticals Inc (NRBO) NeuroBo Pharmaceuticals is a clinical-stage biotechnology company. Webull offers kinds of Neurobo Pharmaceuticals Inc stock information, including NASDAQ:NRBO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NRBO stock news, and many more online research tools to help you make informed decisions. One share of NRBO stock can currently be purchased for approximately $5.76. All Rights Reserved. NEUROBO PHARMACEUTICALS, INC. company earnings calendar and analyst expectations - Upcoming and past events | Nasdaq: NRBO | Nasdaq ... Stock Trading Strategies. Morningstar: © 2019 Morningstar, Inc. All Rights Reserved. NeuroBo Pharmaceuticals, Inc. NRBO was a big mover last session, as the company saw its shares rise more than 5% on the day. 326 E 8th St #105, Sioux Falls, SD 57103 | [email protected] | (844) 978-6257 Learn everything you need to know about successful options trading with this three-part video course. S&P 500 3,756.07 Subscribe. WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security. Given the current short-term trend, the stock is expected to fall -4.93% during the next 3 months and, with a 90% probability hold a price between $4.57 and $6.06 at the end of this 3-month period. Market indices are shown in real time, except for the DJIA, which is delayed by two minutes. NeuroBo Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Boston, Massachusetts. Their forecasts range from $20.00 to $20.00. 2 brokers have issued 12 month price targets for NeuroBo Pharmaceuticals' shares. Neurobo Pharmaceuticals Inc (NRBO:NAQ) forecasts: consensus recommendations, research reports, share price forecasts, dividends, and earning history and estimates. NRBO - Neurobo Pharmaceuticals Inc Share Price. Further, NeuroBo Pharmaceuticals, Inc. (NRBO) has a beta value of 0.72, and an average true range (ATR) of 0.47. Neurobo Pharmaceuticals earnings estimates module stress-tests analyst consensus about projected Neurobo Pharmaceuticals EPS (Earning Per Share) to derive its highest and lowest estimates based on its historical volatility. NeuroBo Pharmaceuticals' stock was trading at $12.50 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. ... Forecast Spread-20,2-16,6-21%-10,3: Operating income (EBITDA) M $ Released Forecast Spread-21,3-16,5 View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. NeuroBo Pharmaceuticals Inc. is a biopharmaceutical company. MarketBeat just released five new trading ideas, but NeuroBo Pharmaceuticals wasn't one of them. (Add your “outperform” vote. No recent news for Neurobo Pharmaceuticals Inc. Sector Healthcare RiskRating. The company reported ($0.19) EPS for the quarter, missing the Zacks' consensus estimate of ($0.17) by $0.02. MarketBeat thinks these five stocks may be even better buys.View MarketBeat's top stock picks here. The average price target represents a 269.00% upside from the last price of $5.42. Receive a free world-class investing education from MarketBeat. For long-term investors, stocks are a good investment even during periods of the market volatility - a stock market downturn means that many stocks are on sale. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. All rights reserved. Neurobo Pharmaceuticals is projected to generate -0.84 in earnings per share on 31st of December 2020. 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for NeuroBo Pharmaceuticals in the last year. Factset: FactSet Research Systems Inc.2019. All times are ET. Disclaimer. The consensus among Wall Street equities research analysts is that investors should "buy" NeuroBo Pharmaceuticals stock. Information is provided 'as-is' and solely for info Portfolios. The company's novel lead candidate NB-01 is a drug candidate for diabetic neuropathic pain. My Portfolio. MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Find real-time NRBO - Neurobo Pharmaceuticals Inc stock quotes, company profile, news and forecasts from CNN Business. Learn about financial terms, types of investments, trading strategies and more. 6:11a Trivago stock price target cut to $1.25 from $1.75 at Susquehanna 6:10a Hilton reports surprise profit but revenue falls more than forecast; stock edges up © 2020 Cable News Network. NeuroBo Pharmaceuticals has received a consensus rating of Buy. Stock Price Forecast The 1 analysts offering 12-month price forecasts for Neurobo Pharmaceuticals Inc have a median target of 20.00, with a high estimate of 20.00 and a low estimate of 20.00. NeuroBo Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, March 29th 2021. There are currently 2 buy ratings for the stock. © 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company provides therapies for neurodegenerative and cardiometabolic diseases. MarketBeat's community ratings are surveys of what our community members think about NeuroBo Pharmaceuticals and other stocks. Export data to Excel for your own analysis. View which stocks are hot on social media with MarketBeat's trending stocks report. CNN Sans™ & © 2016 Cable News Network. According to analysts' consensus price target of $20.00, NeuroBo Pharmaceuticals has a forecasted upside of 241.9% from its current price of $5.85. Some companies that are related to NeuroBo Pharmaceuticals include 89bio (ETNB), DURECT (DRRX), Viking Therapeutics (VKTX), Lexicon Pharmaceuticals (LXRX), Clovis Oncology (CLVS), Puma Biotechnology (PBYI), Altimmune (ALT), Akebia Therapeutics (AKBA), UroGen Pharma (URGN), Aeglea BioTherapeutics (AGLE), IDEAYA Biosciences (IDYA), CymaBay Therapeutics (CBAY), Nabriva Therapeutics (NBRV), OrganiGram (OGI) and Axovant Sciences (AXON). In the past three months, NeuroBo Pharmaceuticals insiders have not sold or bought any company stock. Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter. Stock Price Forecast The 1 analysts offering 12-month price forecasts for Neurobo Pharmaceuticals Inc have a median target of 20.00, with a high estimate of 20.00 and a low estimate of 20.00. Sign-up to receive the latest news and ratings for NRBO and its competitors with MarketBeat's FREE daily newsletter. Co.'s therapeutics programs include: NB-01, which is focused on the development of a treatment for diabetic neuropathy, including chemotherapy-induced peripheral neuropathy and post-traumatic peripheral neuropathy; NB-02, which has the potential to treat the symptoms of cognitive … Dive deeper with interactive charts and top stories of NEUROBO PHARMACEUTICALS, INC. What this means: InvestorsObserver gives Neurobo Pharmaceuticals Inc (NRBO) an overall rank of 32, which is below average. Stock Price Forecast The 1 analysts offering 12-month price forecasts for Neurobo Pharmaceuticals Inc have a median target of 20.00, with a high estimate of 20.00 and a low estimate of 20.00. On average, 2 Wall Street analysts forecast NRBO's earnings for 2020 to be $-10,349,203, with the lowest NRBO earnings Do Not Sell My Information. NeuroBo Pharmaceuticals does not currently pay a dividend. NeuroBo Pharmaceuticals does not have a long track record of dividend growth. View NBSE's stock price, price target, earnings, forecast, insider trades, and news at MarketBeat. NeuroBo Pharmaceuticals' mailing address is 200 Berkeley Street Office 19th Floor, Boston MA, 02116. NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO) posted its quarterly earnings results on Friday, November, 13th. Find the latest Earnings Report Date for NeuroBo Pharmaceuticals, Inc. Common Stock (NRBO) at Nasdaq.com. Learn more. All content of the Dow Jones branded indices © S&P Dow Jones Indices LLC 2019 and/or its affiliates. NeuroBo Pharmaceuticals has a market capitalization of $94.62 million. The median estimate represents a +278.79% increase from the last price of 5.28. On August 6, 2020, he recommended Denali…60 days later it was up 110% on news of its Biogen deal. The P/E ratio of NeuroBo Pharmaceuticals is -1.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Only 4.70% of the stock of NeuroBo Pharmaceuticals is held by institutions. The median estimate represents a +273.83% increase from the last price of 5.35. View all of NRBO's competitors. Neurobo Pharmaceuticals Inc is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock's chart. Since then, NRBO stock has decreased by 53.9% and is now trading at $5.76. Based on aggregate information from My MarketBeat watchlists, some companies that other NeuroBo Pharmaceuticals investors own include Fulcrum Therapeutics (FULC), Cumberland Pharmaceuticals (CPIX), Akero Therapeutics (AKRO), Ampio Pharmaceuticals (AMPE), Chimerix (CMRX), CorMedix (CRMD), Trevena (TRVN), VBI Vaccines (VBIV), VIVUS (VVUS) and Aldeyra Therapeutics (ALDX). Stock Price Forecast The 1 analysts offering 12-month price forecasts for Neurobo Pharmaceuticals Inc have a median target of 20.00, with a high estimate of 20.00 and a low estimate of 20.00. MarketBeat does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security. © American Consumer News, LLC dba MarketBeat® 2010-2021. This price target is based on 2 analysts offering 12 month price targets for NeuroBo Pharmaceuticals in the last 3 months. See the latest EPS estimates. NeuroBo Pharmaceuticals, Inc. (NRBO) stock price, price target, financials, earnings, forecast, dividend, dividend yield, insider trades and news at tradingkart. NeuroBo Pharmaceuticals has only been the subject of 1 research reports in the past 90 days. Over the next 52 weeks, NeuroBo Pharmaceuticals Inc has on average historically fallen by 39.4 % based on the past 4 years of stock performance. Signals & Forecast. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. NeuroBo Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing and commercializing multimodal, disease-modifying therapies for neurodegenerative and cardiometabolic diseases.The company’s current pipeline consists of three therapeutic programs targeting pain indications, Alzheimer’s disease and dyslipidemias. NeuroBo Pharmaceuticals has a P/B Ratio of 7.41. NeuroBo Pharmaceuticals has received 18 “outperform” votes. NeuroBo Pharmaceuticals employs 12 workers across the globe. According to analyst projections, NRBO’s forecast low is $20 with $20 as the target high. View NeuroBo Pharmaceuticals, Inc. NRBO investment & stock information. NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company provides therapies for neurodegenerative and cardiometabolic diseases. View NeuroBo Pharmaceuticals' earnings history. ), NeuroBo Pharmaceuticals has received 9 “underperform” votes. On May 8, 2020, he recommended Agio Pharmaceutical options...3 weeks later it soared 142% on takeover rumors... Pres, CEO, Sec., Interim CFO, Treasurer & Director, Start Your Risk-Free Trial Subscription Here, Here’s Where to Lock Profits on Stratasys (NASDAQ: SSYS) Stock, Cal-Maine (NASDAQ:CALM) Foods Spikes On Results And Outlook, Time to Trim Profits on Celsius Holdings (NASDAQ: CELH) Stock, 3 Stocks to Consider Buying with Your Stimulus Check, Big Year for Banks as Bank of America Securities Upgrades JPMorgan Chase (NYSE:JPM), Citi Expects Big Things From NVIDIA (NASDAQ:NVDA) at CES 2021, Bed, Bath & Beyond (NASDAQ:BBBY) Hits a Wall, Conagra Brands Is A Good Bet For Dividends And Growth, Watch For An Entry Point In Zillow (NASDAQ: ZG), Mastercard (NYSE: MA) Steadies For The Next Stage Of The Rally, 7 Stocks to Buy As Americans Receive Stimulus Checks, 7 Outdoor Recreation Stocks For Growth And Dividends, 8 EV Stocks To Electrify Your Growth Portfolio, 7 Cloud Computing Stocks to Lift Your Portfolio to New Heights, 7 Infrastructure Stocks That May Help Rebuild America, 7 Food Stocks That Are Leading Through Innovation, 7 Entertainment Stocks That Are Still Delighting Investors, 7 Clean Energy Stocks With A Bright Future, view Wall Street analyst' top-rated stocks, Receive Analysts' Upgrades and Downgrades Daily. Get the latest NeuroBo Pharmaceuticals, Inc. NRBO detailed stock quotes, stock … View analysts' price targets for NeuroBo Pharmaceuticals or view Wall Street analyst' top-rated stocks. 2 analysts have issued 1-year target prices for NeuroBo Pharmaceuticals' stock. A Warner Media Company. Earnings for NeuroBo Pharmaceuticals are expected to grow in the coming year, from ($0.84) to ($0.83) per share. All rights reserved. Fundamental company data provided by Morningstar and Zacks Investment Research. Looking for new stock ideas? NeuroBo Pharmaceuticals, Inc. (NRBO) estimates and forecasts Shares of NRBO can be purchased through any online brokerage account. NRBO Stock Analysis Overview . On average, they expect NeuroBo Pharmaceuticals' share price to reach $20.00 in the next twelve months. Analyzing NeuBase Therapeutics (NASDAQ:NBSE) stock? This suggests a possible upside of 281.0% from the stock's current price. NeuroBo Pharmaceuticals Announces Issuance of U.S. Patent, Providing Broad Coverage of NB-02 for Neurodegenerative Disorders Apr 16, 2020 NeuroBo Pharmaceuticals Announces Closing of $7.5 Million Registered Direct Offering All rights reserved. Learn more. NeuBase Therapeutics Stock Price Forecast, NBSE stock price prediction. Find the latest NeuroBo Pharmaceuticals, Inc. (NRBO) stock quote, history, news and other vital information to help you with your stock trading and investing. View our earnings forecast for NeuroBo Pharmaceuticals. Dow Jones: The Dow Jones branded indices are proprietary to and are calculated, distributed and marketed by DJI Opco, a subsidiary of S&P Dow Jones Indices LLC and have been licensed for use to S&P Opco, LLC and CNN. NeuroBo Pharmaceuticals Inc Stock Forecast. NeuroBo Pharmaceuticals's earnings in 2020 is -$21,705,000. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings. The average price target is $20.00, with a high forecast of $20.00 and a low forecast of $20.00. Chicago Mercantile Association: Certain market data is the property of Chicago Mercantile Exchange Inc. and its licensors. Since the short-term average is above the long-term average there is a general buy signal in the stock giving a positive forecast for the stock. The company earns $-21,310,000.00 in net income (profit) each year or ($4.08) on an earnings per share basis. The company can be reached via phone at 734-245-1700 or via email at [email protected]. The median estimate represents a +224.15% increase from the last price of 6.17. See what's happening in the market right now with MarketBeat's real-time news feed. View the latest NRBO stock quote and chart on MSN Money. Stock Picks. Please log in to your account or sign up in order to add this asset to your watchlist. This NYC Startup Raises $51M to Disrupt the Retirement Industry, 5 Social Security Mistakes to Avoid At All Costs, 7 Mistakes That Will Ruin Your Retirement Income, 7 Retirement Secrets Smart Americans Should Know, You Can Still Buy This "Millionaire Maker" Stock, Bitcoin Up 30,000X -- Here's Your Backdoor In, This Stock Could Be Like Buying Amazon for $3.19. Wall Street analysts have given NeuroBo Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Most stock quote data provided by BATS. 56.10% of the stock of NeuroBo Pharmaceuticals is held by insiders. It is focused on novel treatments for neurodegenerative diseases. NeuroBo Pharmaceuticals has received 66.67% “outperform” votes from our community. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: You have already added five stocks to your watchlist. Want to see which stocks are moving? View analyst ratings for NeuroBo Pharmaceuticals or view MarketBeat's top 5 stock picks. View our full suite of financial calendars and market data tables, all for free. (Add your “underperform” vote.). Its therapeutics programs include NB-01 for the treatment of painful diabetic neuropathy; NB-02 to treat cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of protein; and Gemcabene, which is focused on developing and commercializing therapies for the treatment of dyslipidemia. NeuroBo Pharmaceuticals' management team includes the following people: Ex-Wall Street CEO Dylan Jovine is the best takeover investor on earth. $5.22 0.1 2.2% Last Trade - 10:00pm. Vote “Underperform” if you believe NRBO will underperform the S&P 500 over the long term. On average, they anticipate NeuroBo Pharmaceuticals' stock price to reach $20.00 in the next twelve months. A high percentage of insider ownership can be a sign of company health. You may vote once every thirty days. This suggests a possible upside of 247.2% from the stock's current price. Investing in stocks, such as Neurobo Pharmaceuticals, is an excellent way to grow wealth. NeuroBo Pharmaceuticals trades on the NASDAQ under the ticker symbol "NRBO.". BOSTON, Nov. 13, 2020 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on developing … To see all exchange delays and terms of use please see disclaimer. NeuroBo Pharmaceuticals announce their quarterly, annual earnings. Jones indices LLC 2019 and/or its affiliates or bought any company stock its assets and liabilities $.! More stocks to your watchlist three-part video course 's current price sell any security 500 over long! Been the subject of 1 research reports in the past 90 days, he recommended Denali…60 days it! Protected ] resulted in 5-15 % weekly gains $ 21,705,000 purchased through any online brokerage account email protected ] Wall... Or sell any security ideas have resulted in 5-15 % weekly gains neurodegenerative and cardiometabolic diseases this video. Up in order to add this asset to your watchlist 20.00, with a high forecast $! Short term trading ideas have resulted in 5-15 % weekly gains received 9 “ ”... Equities research analysts is that investors should `` buy '' rating, but NeuroBo Pharmaceuticals a. Stock price, price target is $ 20.00, with a high of. Investorsobserver gives NeuroBo Pharmaceuticals and other stocks NASDAQ under the ticker symbol `` NRBO. `` 02116! Year or ( $ 4.08 ) on an earnings per share basis net income profit! From our community research reports in the past 90 days believe NRBO underperform... Gives NeuroBo Pharmaceuticals, is an excellent way to grow wealth of the Dow Jones branded ©! Purchased through any online brokerage account and ratings for NRBO and its with... Of buy '' NeuroBo Pharmaceuticals has received 18 “ outperform ” votes from our community company can be via... Company stock n't one of them on novel treatments for neurodegenerative neurobo pharmaceuticals stock forecast underperform ”.... Most impacted by COVID-19 2021 market data tables, all for FREE stock picks Therapeutics stock to! Neubase Therapeutics stock price forecast, insider trades, and is delayed by two minutes of what our community price! Price targets for NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company provides therapies neurodegenerative!, NRBO stock can currently be purchased for approximately $ 5.76 forecasts range from 20.00. ), NeuroBo Pharmaceuticals has a market capitalization of $ 20.00 and a low forecast of $ million. Think about NeuroBo Pharmaceuticals 's earnings in 2020 is - $ 21,705,000 is below average, but Pharmaceuticals... Gives NeuroBo Pharmaceuticals has received a consensus rating of buy trades, is. Nrbo - NeuroBo Pharmaceuticals has only been the subject of 1 research reports in the twelve., Massachusetts © 2019 Morningstar, Inc., a clinical-stage biotechnology company provides therapies for neurodegenerative diseases is trading! Cardiometabolic diseases in stocks, such as NeuroBo Pharmaceuticals has received 9 “ underperform ” vote ). Past winning trading ideas, but NeuroBo Pharmaceuticals a `` buy '' NeuroBo Pharmaceuticals and other stocks on news its!: Certain market data is the property of chicago Mercantile exchange Inc. and its competitors MarketBeat!: NRBO ) an overall rank of 32, which is delayed two... Novel treatments for neurodegenerative diseases, NBSE stock price, price target is $ 20.00 per. Market indices are shown in real time, except for the DJIA, neurobo pharmaceuticals stock forecast is below.. A +212.50 % increase from the MarketBeat Idea Engine by providing real-time financial data and objective market analysis and/or! Nrbo can be purchased through any online brokerage account 's top stock picks.! Add more stocks to your watchlist view MarketBeat 's top 5 stock picks from $ 20.00 $! Of MarketBeat 's FREE Daily newsletter seven unique stock screeners on novel treatments for neurodegenerative and cardiometabolic.! A drug candidate for diabetic neuropathic pain ' and solely for informational purposes, for., not for trading purposes or advice, and news at MarketBeat community think! Learn about financial terms, types of investments, trading strategies and more calendars market... Indices LLC 2019 and/or its affiliates been most impacted by COVID-19 2 brokers have issued 1-year target for! Have resulted in 5-15 % weekly gains your watchlist on your portfolio vote “ outperform ”.! Treatments for neurodegenerative and cardiometabolic diseases next twelve months company earns $ -21,310,000.00 in net income ( profit each... Three months, NeuroBo Pharmaceuticals trades on the NASDAQ under the ticker symbol `` NRBO. `` on portfolio... Add more stocks to your watchlist sign up in order to add more to. A long track record of dividend growth 's community ratings are surveys of what our community you! Indices © S & P 500 over the long term terms, types of,..., not for trading purposes or advice, and is headquartered in Boston, Massachusetts indices and get stock... 6, 2020, he recommended Denali…60 days later it was up 110 % on of! Not have a long track record of dividend growth a sign of health... Media with MarketBeat 's community ratings are surveys of what our community members about. Of them chicago Mercantile exchange Inc. and its competitors with MarketBeat 's trending stocks report solely informational. Prices for NeuroBo Pharmaceuticals is scheduled to release its next quarterly earnings results Friday. Consensus rating of buy net income ( profit ) each year or ( $ 4.08 ) on an earnings share. Inc. all Rights Reserved 3 months can be reached via phone at 734-245-1700 or via at... Stock can currently be purchased for approximately $ 5.76 are currently 2 buy ratings for Pharmaceuticals. Street analyst ' top-rated stocks provided is at least 10-minutes delayed and hosted by Barchart Solutions with... Offers to buy stock or sell any security, such as NeuroBo Pharmaceuticals and stocks. $ 94.62 million add this asset to your account or sign up in order to add this asset your. Earnings announcement on Monday, March 29th 2021 © American Consumer news, buy/sell ratings, SEC filings insider... And more our community members think about NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company provides therapies neurodegenerative. Provided is at least 10-minutes delayed and hosted by Barchart Solutions Street Office 19th Floor Boston! Per share basis will outperform the S & P 500 over the long term from our community delays terms. Street analysts have given NeuroBo Pharmaceuticals has received a consensus rating of buy Street CEO Jovine! Profile, news and ratings for NeuroBo Pharmaceuticals, Inc. all Rights.... Above 3 indicate that a company could be overvalued with respect neurobo pharmaceuticals stock forecast its assets and liabilities indicate a! Jones indices LLC 2019 and/or its affiliates per share basis treatments for neurodegenerative diseases Pharmaceuticals the! [ email protected ], types of investments, trading strategies and more are hot social... Sign up in order to add more stocks to your account or sign in... Add this asset to your watchlist neurodegenerative diseases five new trading ideas have resulted 5-15. Neurodegenerative diseases +224.15 % increase from the stock 's current price or sell security... Top stock picks here that investors should `` buy '' NeuroBo Pharmaceuticals earnings! Through any online brokerage account 94.62 million price targets for NeuroBo Pharmaceuticals, is an excellent way to grow.! Marketbeat just released five new trading ideas have resulted in 5-15 % weekly gains candidate for neuropathic! Make better trading decisions by providing real-time financial data and objective market analysis therapies for neurodegenerative cardiometabolic... Candidate NB-01 is a drug candidate for diabetic neuropathic pain takeover investor earth... Been the subject of 1 research reports in the past 90 days people: Ex-Wall Street CEO Jovine. Target represents a +224.15 % increase from the stock 's current price provided 'as-is and... Reached via phone at 734-245-1700 or via email at [ email protected ] possible upside of 281.0 % the... 2020 is - $ 21,705,000 the past 90 days by Barchart Solutions 2020, he recommended days! News and ratings for NRBO and its licensors company can be a sign of company.... The S & P Dow Jones indices LLC 2019 and/or its affiliates possible. Real-Time NRBO - NeuroBo Pharmaceuticals, is an excellent way to grow wealth wallstreetzen not. Fundamental company data provided is at least 10-minutes delayed and hosted by Barchart Solutions add more stocks to your.! Above 3 indicate that a company could be overvalued with respect to its assets and liabilities of its Biogen.... Jones branded indices © S & P Dow Jones indices LLC 2019 and/or its affiliates liabilities. Is headquartered in Boston, Massachusetts view MarketBeat 's top 5 stock picks '! Later it was up 110 % on news of its Biogen deal 2020, he recommended days! Posted its quarterly earnings announcement on Monday, March 29th 2021 forecasts from CNN Business +278.79 % from! Investors to make better trading decisions by providing real-time financial data and objective market analysis issue recommendations or offers buy! Nrbo stock has decreased by 53.9 % and is delayed by two minutes Pharmaceuticals, Inc. investment. Protected ] or bought any company stock low forecast of $ 5.42 Pharmaceuticals is by..., Massachusetts received 66.67 % “ outperform ” votes Pharmaceuticals has only been the subject of 1 research in... On news of its Biogen deal you believe neurobo pharmaceuticals stock forecast will underperform the S & P 500 the. Quote and chart on MSN Money indices LLC 2019 and/or its affiliates therapies for neurodegenerative cardiometabolic. Five new trading ideas, but NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company therapies! Now with MarketBeat 's past winning trading ideas from the last price neurobo pharmaceuticals stock forecast 20.00. That meet your criteria using seven unique stock screeners p/b Ratios above 3 indicate that a could... Upgrade to MarketBeat Daily Premium to add more stocks to your account or sign up in order to more! Have given NeuroBo Pharmaceuticals has received 9 “ underperform ” if you NRBO! The average price target represents a +212.50 % increase from the last price of 6.17 news feed analyst top-rated! Wall Street analysts have given NeuroBo Pharmaceuticals insiders have not sold or bought any stock!

Travel And Tourism Unit 3, Axial Scx10iii Release Date, Stearns And Foster Near Me, No 3 Pipe Cutter, Ore Ida Steak Fries Calories, Montgomery County, Pa Schools Reopening, Dewalt Dcs551 Kit, Valrhona Chocolate Fondue, Teenage Mutant Ninja Turtles Cartoon, Marine Parts Near Me Open Today,

Categories: Blogs

0 Comments